Marksans Pharma Ltd
MARKSANS
Company Profile
Business description
Marksans Pharma Ltd is a pharmaceutical company. The company is engaged in the research, manufacturing, and marketing of pharmaceutical formulations. It manufactures analgesics, gastroenterology, anti-diabetic, cardiovascular, pain management, gynecology, gastrointestinal, and oncologic drugs as well as antibiotics and antiallergic medications. Geographically, the majority of its revenue is generated from the United States and North America, followed by Europe and the UK, Australia and New Zealand, and the Rest of the World.
Contact
Veera Desai Extension Road
11th Floor, Grandeur
Opposite Gundecha Symphony
Oshiwara, Andheri (West)
MumbaiMH400053
INDT: +91 2240012000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 March 2027
Employees
2,235
Stocks News & Analysis
stocks
Chip stock selloff deepens in Asia, extends to Europe and US
The week’s tech stock rout continues despite strong earnings from TSMC and ASML.
stocks
Downgrade for ASX listed fund manager as redemptions pile on
Persistent outflows erode earnings outlook.
stocks
Tesla stock is down nearly 20% this year. Is it a buy ahead of earnings?
Following the rollout of its first autonomous Cybercab, here’s what we expect from Tesla’s earnings report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,942.90 | 102.50 | 1.16% |
| CAC 40 | 7,934.70 | 61.59 | 0.78% |
| DAX 40 | 25,382.62 | 84.01 | 0.33% |
| Dow JONES (US) | 52,177.69 | 556.21 | 1.08% |
| FTSE 100 | 10,840.35 | 115.49 | 1.08% |
| HKSE | 24,353.69 | 290.97 | 1.21% |
| NASDAQ | 26,713.03 | 20.16 | 0.08% |
| Nikkei 225 | 65,644.29 | 1,218.34 | 1.89% |
| NZX 50 Index | 13,753.73 | 79.07 | -0.57% |
| S&P 500 | 7,744.06 | 25.12 | 0.33% |
| S&P/ASX 200 | 8,810.10 | 90.40 | 1.04% |
| SSE Composite Index | 3,742.66 | 35.18 | 0.95% |